Quantum BioPharma Shareholders Approve Corporate Measures at Annual Meeting

Quantum BioPharma Ltd. reported the successful completion of its annual general and special meeting of shareholders held on September 26, 2025, in Toronto. The meeting saw significant shareholder participation with holders of 12 Class A multiple voting shares and 1,769,228 Class B subordinate voting shares present either in person or by proxy. This represented 100% of Class A votes and 46.352% of Class B votes, indicating substantial investor engagement in the company's governance matters.

The meeting's importance lies in the shareholder approval of various corporate measures that will guide Quantum BioPharma's strategic direction. As a biopharmaceutical company focused on developing treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, these shareholder decisions provide crucial validation for the company's ongoing research and development initiatives. The company maintains its commitment to building a portfolio of innovative assets and biotech solutions through its various subsidiaries and strategic investments.

Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma continues advancing its lead compound Lucid-MS, a patented new chemical entity that has demonstrated potential in preventing and reversing myelin degradation in preclinical models. This mechanism addresses the underlying pathology of multiple sclerosis, representing a significant area of therapeutic development. The company's portfolio also includes its unbuzzd technology, with Quantum BioPharma retaining 20.11% ownership in Unbuzzd Wellness Inc. as of March 31, 2025, along with royalty arrangements that provide ongoing revenue potential.

The shareholder meeting outcomes reinforce investor confidence in Quantum BioPharma's diversified approach to pharmaceutical development. The company maintains full rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses, preserving its strategic flexibility in the competitive biopharmaceutical landscape. Additional information about the company's developments is available through its corporate communications channels at https://ibn.fm/QNTM.

Quantum BioPharma's strategic investments are managed through its wholly owned subsidiary FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. This diversified investment approach complements the company's core pharmaceutical research activities, providing additional financial stability as it advances its drug development pipeline. The successful shareholder meeting demonstrates ongoing support for the company's multifaceted strategy in the evolving biopharmaceutical sector.